Name
RF5-03: OlympiaN phase 2 results: efficacy and safety of neoadjuvant olaparib monotherapy and olaparib + durvalumab in patients with BRCO mutations and early-stage HER2-negative BC - Commentary by: William Gradishar, MD, FASCO, FACP
Date & Time
Thursday, December 4, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL